<!DOCTYPE html>
<html lang="ja">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Pharma Daily Brief | PiercePharma 朝刊</title>
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Noto+Sans+JP:wght@400;500;600;700&family=IBM+Plex+Sans:wght@400;500;600&display=swap" rel="stylesheet">
  <style>
    :root {
      --bg-main: #0f1419;
      --bg-card: #1a2332;
      --bg-card-hover: #232f42;
      --text-primary: #e8edf4;
      --text-secondary: #94a3b8;
      --text-muted: #64748b;
      --accent-pipeline: #38bdf8;
      --accent-regulatory: #fb923c;
      --accent-deals: #4ade80;
      --accent-earnings: #a78bfa;
      --border: #2d3a4f;
      --link: #7dd3fc;
      --link-hover: #bae6fd;
    }
    * { box-sizing: border-box; margin: 0; padding: 0; }
    body { font-family: 'IBM Plex Sans', 'Noto Sans JP', sans-serif; background: var(--bg-main); color: var(--text-primary); line-height: 1.6; min-height: 100vh; padding: 24px 16px; }
    .container { max-width: 720px; margin: 0 auto; }
    .header { margin-bottom: 32px; padding-bottom: 20px; border-bottom: 1px solid var(--border); }
    .header h1 { font-size: 1.5rem; font-weight: 700; letter-spacing: -0.02em; }
    .header .date { font-size: 0.875rem; color: var(--text-muted); margin-top: 4px; font-weight: 500; }
    .header .subtitle { font-size: 0.8125rem; color: var(--text-secondary); margin-top: 8px; }
    .header .scope { font-size: 0.75rem; color: var(--text-muted); margin-top: 12px; padding: 10px 12px; background: var(--bg-card); border-radius: 6px; border: 1px solid var(--border); line-height: 1.5; }
    .header .scope strong { color: var(--text-secondary); }
    .category-section { margin-bottom: 28px; }
    .category-header { display: flex; align-items: center; gap: 8px; margin-bottom: 12px; font-size: 0.8125rem; font-weight: 600; text-transform: uppercase; letter-spacing: 0.05em; }
    .category-header .badge { width: 8px; height: 8px; border-radius: 50%; }
    .category-pipeline .badge { background: var(--accent-pipeline); } .category-pipeline .category-header { color: var(--accent-pipeline); }
    .category-regulatory .badge { background: var(--accent-regulatory); } .category-regulatory .category-header { color: var(--accent-regulatory); }
    .category-deals .badge { background: var(--accent-deals); } .category-deals .category-header { color: var(--accent-deals); }
    .category-earnings .badge { background: var(--accent-earnings); } .category-earnings .category-header { color: var(--accent-earnings); }
    .article-card { background: var(--bg-card); border: 1px solid var(--border); border-left: 3px solid; border-radius: 8px; padding: 16px; margin-bottom: 12px; transition: background 0.2s; }
    .article-card:hover { background: var(--bg-card-hover); }
    .article-card.pipeline { border-left-color: var(--accent-pipeline); }
    .article-card.regulatory { border-left-color: var(--accent-regulatory); }
    .article-card.deals { border-left-color: var(--accent-deals); }
    .article-card.earnings { border-left-color: var(--accent-earnings); }
    .article-card .title { font-size: 1rem; font-weight: 600; margin-bottom: 8px; line-height: 1.4; }
    .article-card .title a { color: var(--text-primary); text-decoration: none; transition: color 0.2s; }
    .article-card .title a:hover { color: var(--link-hover); }
    .article-card .summary { font-size: 0.875rem; color: var(--text-secondary); margin-bottom: 10px; line-height: 1.5; }
    .article-card .meta { display: flex; flex-wrap: wrap; gap: 12px; font-size: 0.75rem; color: var(--text-muted); }
    .article-card .meta span { display: inline-flex; align-items: center; gap: 4px; }
    .article-card .link-wrap { margin-top: 10px; }
    .article-card .link-wrap a { font-size: 0.8125rem; color: var(--link); text-decoration: none; transition: color 0.2s; }
    .article-card .link-wrap a:hover { color: var(--link-hover); text-decoration: underline; }
    .article-card .link-wrap a::after { content: '→'; }
    .importance { display: inline-flex; gap: 2px; }
    .importance .star { color: var(--accent-regulatory); font-size: 0.7rem; }
    .importance .star.empty { color: var(--text-muted); opacity: 0.5; }
    .article-card .meta .region { font-size: 0.7rem; padding: 2px 6px; border-radius: 4px; font-weight: 500; }
    .region-us { background: rgba(56,189,248,0.2); color: var(--accent-pipeline); }
    .region-europe { background: rgba(251,146,60,0.2); color: var(--accent-regulatory); }
    .region-china { background: rgba(74,222,128,0.2); color: var(--accent-deals); }
    @media (max-width: 480px) { body { padding: 16px 12px; } .header h1 { font-size: 1.25rem; } .article-card { padding: 14px; } }
  </style>
</head>
<body>
  <div class="container">
    <header class="header">
      <h1>Pharma Daily Brief</h1>
      <div class="date">2026年02月25日（水）</div>
      <div class="subtitle">パイプライン・規制・M&A・決算｜医薬・バイオ業界の重要ニュース（毎朝更新）</div>
      <div class="scope">
        <strong>対象地域：</strong>約9割は米国。欧州はノボノルディスク、ブリストルマイヤーズスクイーブ、サノフィ、ロッシュ、バイエルなど大手の重要ニュースを追加。中国は個別企業より<strong>医薬品規制当局の動向</strong>（変化が大きい場合）を掲載。
      </div>
    </header>


    <section class="category-section category-pipeline">
      <h2 class="category-header">
        <span class="badge"></span>
        Pipeline
      </h2>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/bridgebios-launch-attruby-accelerates-ceo-says-company-will-rely-its-differentiation" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/bridgebios-launch-attruby-accelerates-ceo-says-company-will-rely-its-differentiation&quot; hreflang=&quot;en&quot;&gt;As BridgeBio&#x27;s Attruby launch accelerates, CEO shrugs off recent EU pricing pressure fears&lt;/a&gt;</a></h3>
        <p class="summary">When BridgeBio presented its quarterly report on Tuesday, it laid out expectations on the potential threat of generic pricing pressure on Attruby and provided more evidence of the drug&#x27;s strong launch…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/bridgebios-launch-attruby-accelerates-ceo-says-company-will-rely-its-differentiation" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/cro/charles-river-sells-manufacturing-and-discovery-businesses-fulfill-promised-strategic-pivot" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/cro/charles-river-sells-manufacturing-and-discovery-businesses-fulfill-promised-strategic-pivot&quot; hreflang=&quot;en&quot;&gt;Charles River sells manufacturing and discovery businesses to fulfill promised pivot&lt;/a&gt;</a></h3>
        <p class="summary">After promising to sell off 7% of its business back in November, Charles River Laboratories has delivered. The CRO is offloading its entire contract manufacturing operation and some of its European di…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/cro/charles-river-sells-manufacturing-and-discovery-businesses-fulfill-promised-strategic-pivot" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/gilead-paints-clearer-picture-bictegravir-lenacapavir-single-tablet-combos-prowess-varied" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/gilead-paints-clearer-picture-bictegravir-lenacapavir-single-tablet-combos-prowess-varied&quot; hreflang=&quot;en&quot;&gt;Gilead paints clearer picture of next-gen HIV tablet&#x27;s prowess with results from 2 late-stage studies&lt;/a&gt;</a></h3>
        <p class="summary">The company unveiled detailed results from its pair of late-stage Artistry trials this week at the Conference on Retroviruses and Opportunistic Infections (CROI) in Denver.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/gilead-paints-clearer-picture-bictegravir-lenacapavir-single-tablet-combos-prowess-varied" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/marketing/reach-consumers-interested-glp-1s-audio-dramatically-underutilized-siriusxm-survey" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/marketing/reach-consumers-interested-glp-1s-audio-dramatically-underutilized-siriusxm-survey&quot; hreflang=&quot;en&quot;&gt;To reach consumers interested in GLP-1s, audio is ‘dramatically underutilized’: SiriusXM survey&lt;/a&gt;</a></h3>
        <p class="summary">In developing media plans to reach the GLP-1-interested consumer, audio advertising may represent a “blind spot,” according to Anna Clement, director head of industry for SiriusXM Media’s pharma verti…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/marketing/reach-consumers-interested-glp-1s-audio-dramatically-underutilized-siriusxm-survey" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/biotech/worried-mfn-will-destroy-biotech-innovation-midsize-biotechs-form-coalition-fight-back" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/biotech/worried-mfn-will-destroy-biotech-innovation-midsize-biotechs-form-coalition-fight-back&quot; hreflang=&quot;en&quot;&gt;Worried Trump&#x27;s MFN push will ‘destroy biotech innovation,’ midsize companies form coalition to fight back&lt;/a&gt;</a></h3>
        <p class="summary">In an effort to battle against what members feel is an existential threat to their businesses, a group of 10 domestic biotech companies has launched the Midsized Biotech Alliance of America with a foc…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/biotech/worried-mfn-will-destroy-biotech-innovation-midsize-biotechs-form-coalition-fight-back" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/marketing/sanofi-assists-bostons-world-cup-plans-play-engagement" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/marketing/sanofi-assists-bostons-world-cup-plans-play-engagement&quot; hreflang=&quot;en&quot;&gt;Sanofi assists Boston’s World Cup plans with play for local engagement&lt;/a&gt;</a></h3>
        <p class="summary">Sanofi has kicked off its preparations for the 2026 World Cup by becoming an official backer of Boston’s involvement in the soccer showcase.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/marketing/sanofi-assists-bostons-world-cup-plans-play-engagement" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/novartis-rounds-out-radiopharmaceutical-plans-amid-broader-23b-us-investment-blitz" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/novartis-rounds-out-radiopharmaceutical-plans-amid-broader-23b-us-investment-blitz&quot; hreflang=&quot;en&quot;&gt;With Texas site, Novartis rounds out radiopharma production plans amid $23B US investment blitz&lt;/a&gt;</a></h3>
        <p class="summary">Novartis is wasting little time sketching out the radiopharmaceutical details of its $23 billion U.S. investment push. Shortly after announcing a new manufacturing facility for the class of cancer med…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/novartis-rounds-out-radiopharmaceutical-plans-amid-broader-23b-us-investment-blitz" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-2026" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-2026&quot; hreflang=&quot;en&quot;&gt;Regulatory tracker: Pfizer&#x27;s Braftovi combo wins full FDA approval in colorectal cancer&lt;/a&gt;</a></h3>
        <p class="summary">In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-2026" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/coallition-15-states-file-lawsuit-against-rfk-jr-cdc-over-new-childhood-vaccine" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/coallition-15-states-file-lawsuit-against-rfk-jr-cdc-over-new-childhood-vaccine&quot; hreflang=&quot;en&quot;&gt;15 states sue RFK Jr. and CDC, challenging new childhood vaccine recommendations&lt;/a&gt;</a></h3>
        <p class="summary">A coalition of 15 states is filing a lawsuit against Robert F. Kennedy Jr. and the Centers for Disease Control and Prevention, challenging their overhaul of the vaccine schedule for children in the U.…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/coallition-15-states-file-lawsuit-against-rfk-jr-cdc-over-new-childhood-vaccine" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/marketing/genedit-rewrites-identity-emerging-breezebio-60m-genetic-medicine-rd" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/marketing/genedit-rewrites-identity-emerging-breezebio-60m-genetic-medicine-rd&quot; hreflang=&quot;en&quot;&gt;GenEdit rewrites identity, emerging as BreezeBio with $60M for genetic medicine R&amp;D&lt;/a&gt;</a></h3>
        <p class="summary">GenEdit is sailing toward the clinic with a new name and fresh funding. Rebranded as BreezeBio, the biotech has raised $60 million to take a drug candidate designed to restore immune tolerance in Type…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/marketing/genedit-rewrites-identity-emerging-breezebio-60m-genetic-medicine-rd" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>
    </section>

    <footer style="margin-top: 40px; padding-top: 20px; border-top: 1px solid var(--border); font-size: 0.75rem; color: var(--text-muted);">
      Pharma Daily Brief — PiercePharma 朝刊 | 米国中心・欧州大手・中国規制を含む医薬・バイオ業界の重要ニュース
    </footer>
  </div>
</body>
</html>